{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T20:22:09Z","timestamp":1794514929789,"version":"4.9.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Teclistamab is the first approved B-cell maturation antigen \u00d7 CD3 bispecific antibody with weight-based dosing for triple-class\u2013exposed relapsed\/refractory multiple myeloma (RRMM). We evaluated the safety and efficacy of teclistamab combined with daratumumab in the phase 1b TRIMM-2 study. Eligible patients had RRMM (\u22653 previous lines of therapy [pLOT] or with disease double-refractory to a proteasome inhibitor and immunomodulatory drug); anti-CD38 exposure was permitted. Patients received subcutaneous daratumumab per approved schedule plus weight-based or fixed-dose subcutaneous teclistamab. The primary end point was safety; secondary end points included overall response rate (ORR) and duration of response (DOR). Progression-free survival (PFS) was exploratory. Sixty-one patients received weight-based, recommended phase 2 doses (RP2D; teclistamab 1.5 mg\/kg weekly or 3.0 mg\/kg every other week); median number of pLOTs was 5 (range, 1-14). Median follow-up was 12.0 months. Common treatment-emergent adverse events (TEAEs) included infections, cytokine release syndrome, neutropenia, and anemia; grade 3\/4 TEAEs occurred in 93.4%; 7 died of TEAEs. Any-grade infections occurred in 82.0% (grade 3\/4 [maximum toxicity], 45.9%; grade 5, 8.2%). No dose-limiting toxicities occurred. ORR was 68.9% (complete response or better, 44.3%); median DOR was not reached. Median PFS was 26.3 months. A cohort exploring fixed-dose teclistamab (100-300 mg) ended prematurely after a safety signal for fatal infections was identified; out of an abundance of caution, all patients were switched to weight-based dosing. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile. Results highlight the importance of infection management, including early immunoglobulin replacement. This trial was registered at www.clinicaltrials.gov as NCT04108195.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020648","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:11:07Z","timestamp":1788387067000},"page":"7586-7596","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Teclistamab and daratumumab immune-based doublet therapy for relapsed\/refractory multiple myeloma: the TRIMM-2 study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"first","affiliation":[{"name":"1Cancer Center Cl\u00ednica Universidad de Navarra, University of Navarra, Pamplona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morillo","sequence":"additional","affiliation":[{"name":"2START Madrid-FJD early phase unit, Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"D\u2019Souza","sequence":"additional","affiliation":[{"name":"3Division of Hematology\/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9686-4323","authenticated-orcid":false,"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"4Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1251-4649","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[{"name":"5Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai School of Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"7Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7011-0286","authenticated-orcid":false,"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"8University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Mar\u00eda-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"9University Hospital of Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Centro de Investigaci\u00f3n del C\u00e1ncer, Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"McKay","sequence":"additional","affiliation":[{"name":"10Atrium Health Wake Forest Baptist Medical, Wake Forest University School of Medicine, Winston-Salem, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-9239","authenticated-orcid":false,"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[{"name":"11Hospital Cl\u00ednic de Barcelona, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna Sureda","family":"Balari","sequence":"additional","affiliation":[{"name":"12Institut Catal\u00e0 d'Oncologia Hospitalet, Institut d\u2019Investigacions Biomediques de Bellvitge, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0813-3444","authenticated-orcid":false,"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[{"name":"13Freiburg University Medical Center, Faculty of Medicine, Freiburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9019-7438","authenticated-orcid":false,"given":"Manisha","family":"Bhutani","sequence":"additional","affiliation":[{"name":"14Division of Hematology, Atrium Health Levine Cancer Institute, Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[{"name":"15University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar","family":"Bahlis","sequence":"additional","affiliation":[{"name":"16Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Department of Oncology, University of Calgary, Calgary, AB, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deeksha","family":"Vishwamitra","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Skerget","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpana","family":"Bakshi","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Guo","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weili","family":"Sun","sequence":"additional","affiliation":[{"name":"18Johnson & Johnson, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna D.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"19Johnson & Johnson, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Stephenson","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-7730","authenticated-orcid":false,"given":"Thomas J.","family":"Prior","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lien","family":"Vandenberk","sequence":"additional","affiliation":[{"name":"20Johnson & Johnson, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangmin","family":"Lee","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Damiette","family":"Smit","sequence":"additional","affiliation":[{"name":"21Johnson & Johnson, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0044-4341","authenticated-orcid":false,"given":"Raluca I.","family":"Verona","sequence":"additional","affiliation":[{"name":"17Johnson & Johnson, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2221","authenticated-orcid":false,"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"22Institut Catal\u00e0 d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8484-175X","authenticated-orcid":false,"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[{"name":"23City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026111214365669700_bib1","doi-asserted-by":"crossref","first-page":"1169541","DOI":"10.3389\/fimmu.2023.1169541","article-title":"Therapeutic strategies to enhance immune response induced by multiple myeloma cells","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"issue":"18","key":"2026111214365669700_bib2","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.3390\/cancers13184546","article-title":"Harnessing the immune system to fight multiple myeloma","volume":"13","author":"Krejcik","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026111214365669700_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ejh.14051","article-title":"CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?","volume":"112","author":"Fischer","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026111214365669700_bib4","doi-asserted-by":"crossref","first-page":"1027385","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front Immunol"},{"key":"2026111214365669700_bib5","unstructured":"GlaxoSmithKline\n          . Blenrep (belantamab mafodotin) combinations approved by UK MHRA in relapsed\/refractory multiple myeloma. Accessed 21 September 2026. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma\/."},{"issue":"1","key":"2026111214365669700_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41408-025-01311-y","article-title":"Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period","volume":"15","author":"Rodriguez-Lobato","year":"2025","journal-title":"Blood Cancer J"},{"key":"2026111214365669700_bib7","volume-title":"TECVAYLI\u00ae (teclistamab-cqyv) injection, for subcutaneous use [package insert]","year":"2026"},{"key":"2026111214365669700_bib8","article-title":"Summary of product characteristics","author":"TECVAYLI","year":"2026","journal-title":"Janssen Biologics BV"},{"key":"2026111214365669700_bib9","author":"Uttervall","year":"11-14  2026"},{"issue":"suppl 16","key":"2026111214365669700_bib10","doi-asserted-by":"crossref","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026111214365669700_bib11","volume-title":"DARZALEX\u00ae (daratumumab) injection [package insert]","year":"2022"},{"issue":"9","key":"2026111214365669700_bib12","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026111214365669700_bib13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1056\/NEJMoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"issue":"8","key":"2026111214365669700_bib14","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026111214365669700_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"6","key":"2026111214365669700_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026111214365669700_bib17","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood-2024-199374","article-title":"Effects of intravenous immunoglobulin supplementation (IVIG) on infections in recipients of teclistamab therapy for multiple myeloma (MM): a multi-institutional study","volume":"144","author":"Cheruvalath","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026111214365669700_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026111214365669700_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026111214365669700_bib20","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026111214365669700_bib21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","article-title":"Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026111214365669700_bib22","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10396","key":"2026111214365669700_bib23","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"6","key":"2026111214365669700_bib24","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3390\/cancers15061819","article-title":"Bispecific antibodies in multiple myeloma: opportunities to enhance efficacy and improve safety","volume":"15","author":"Swan","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2026111214365669700_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"2026111214365669700_bib26","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","article-title":"International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma","volume":"25","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026111214365669700_bib27","doi-asserted-by":"crossref","first-page":"e70585","DOI":"10.1002\/cam4.70585","article-title":"Treatment of multiple myeloma in patients refractory to daratumumab\/anti-CD38 monoclonal antibodies: a systematic review","volume":"14","author":"Tan","year":"2025","journal-title":"Cancer Med"},{"issue":"9","key":"2026111214365669700_bib28","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2026111214365669700_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41408-023-00946-z","article-title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"13","author":"Visram","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026111214365669700_bib30","unstructured":"Our World in Data\n          . COVID-19 Pandemic. Accessed 21 September 2026. https:\/\/ourworldindata.org\/coronavirus."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7586\/2600088\/blooda_adv-2026-020648-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7586\/2600088\/blooda_adv-2026-020648-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:37:11Z","timestamp":1794512231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7586\/570728\/Teclistamab-and-daratumumab-immune-based-doublet"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":30,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020648","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}